Does Rallies show Form 4 insider transactions for CRBU?

Yes. Rallies tracks CRBU insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CRBU research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CRBU. It does not provide personalized investment advice.

CRBU (Caribou Biosciences, Inc. Common Stock) Stock Analysis - Insider Trades

Caribou Biosciences, Inc. Common Stock (CRBU) is a publicly traded Healthcare sector company. As of May 21, 2026, CRBU trades at $2.01 with a market cap of $205.30M and a P/E ratio of -1.24. CRBU moved +0.76% today. Year to date, CRBU is +24.22%; over the trailing twelve months it is +81.82%. Its 52-week range spans $0.66 to $3.54. Analyst consensus is strong buy with an average price target of $9.00. Rallies surfaces CRBU's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CRBU stock inside the company?

Recent CRBU insider activity includes Kelly Timothy P sold 6.23K, Kelly Timothy P sold 3.15K, MCCLUNG BARBARA G sold 6.94K, Khan Ruhi Ahmad sold 6.94K, and Albertson Tina M. sold 1.07K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CRBU Key Metrics

Key financial metrics for CRBU
Metric	Value
Price	$2.01
Market Cap	$205.30M
P/E Ratio	-1.24
EPS	$-1.59
Dividend Yield	0.00%
52-Week High	$3.54
52-Week Low	$0.66
Volume	167
Avg Volume	0
Revenue (TTM)	$11.16M
Net Income	$-148.13M
Gross Margin	0.00%

Recent CRBU Insider Trades

Kelly Timothy P sold 6.23K (~$12.02K) on Feb 25, 2026.
Kelly Timothy P sold 3.15K (~$6.17K) on Feb 24, 2026.
MCCLUNG BARBARA G sold 6.94K (~$13.60K) on Feb 24, 2026.
Khan Ruhi Ahmad sold 6.94K (~$13.60K) on Feb 24, 2026.
Albertson Tina M. sold 1.07K (~$2.09K) on Feb 24, 2026.

Latest CRBU News

Caribou to Present 84-Patient Vispa-cel Durability, 48-Patient CB-011 Follow-Up at EHA — May 12, 2026
Caribou Biosciences Q4 Loss Narrows to $0.28, Revenue Surges 56% to $3.94M — Mar 5, 2026
Caribou Biosciences Shows $148.1M GAAP Loss, Secures $142.8M Cash Runway — Mar 5, 2026
Caribou Biosciences Flags Funding Needs, Forecasts Q4 Loss and $734M CB-011 Sales — Feb 24, 2026
Caribou Biosciences Outlines Pivotal Phase II/III Vispa-cel Trial, Seeks $100M — Feb 23, 2026

CRBU Analyst Consensus

8 analysts cover CRBU: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $9.00.

Common questions about CRBU

Who is trading CRBU stock inside the company?: Recent CRBU insider activity includes Kelly Timothy P sold 6.23K, Kelly Timothy P sold 3.15K, MCCLUNG BARBARA G sold 6.94K, Khan Ruhi Ahmad sold 6.94K, and Albertson Tina M. sold 1.07K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CRBU?: Yes. Rallies tracks CRBU insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CRBU research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CRBU. It does not provide personalized investment advice.